GRCL
Gracell Biotechnologies Inc.
NASDAQ: GRCL · HEALTHCARE · BIOTECHNOLOGY
$10.25
+0.00% today
Updated 2026-10-29
Market cap
$989.87M
P/E ratio
—
P/S ratio
732.21x
EPS (TTM)
$-0.97
Dividend yield
—
52W range
$0 – $0
Volume
6.4M
Gracell Biotechnologies Inc. (GRCL) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Operating cash flow | $-61.86M | $-135.39M | $-198.15M | $-304.55M | $-3.31B | — |
| Capital expenditures | $11.36M | $56.43M | $79.40M | $56.74M | $331.55M | $0.00 |
| Depreciation | — | — | — | — | — | — |
| Stock-based comp | — | — | $0.00 | $60.38M | $165.15M | — |
| Free cash flow | $-73.21M | $-191.82M | $-277.55M | $-361.29M | $-3.64B | — |
| Investing cash flow | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — |
Frequently asked questions
Is GRCL's balance sheet healthy?
GRCL holds $1.45B in cash and equivalents against $46.51M in long-term debt, on $1.38B of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.